Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies

Clinical trial NCT05803928 · UNKNOWN

Trial details

NCT number: NCT05803928
Sponsor: Hua Li
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2024-01-01
Primary completion: 2024-11-01
Enrollment: 70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.